Eli Lilly And Co (NYSE:LLY) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
A number of other equities analysts have also weighed in on the stock. Credit Suisse Group upgraded shares of Eli Lilly And Co from an “underperform” rating to a “neutral” rating in a research report on Wednesday, October 31st. Wolfe Research assumed coverage on shares of Eli Lilly And Co in a research report on Tuesday, October 23rd. They set a “market perform” rating and a $119.00 target price for the company. Cantor Fitzgerald restated a “buy” rating and set a $128.00 target price on shares of Eli Lilly And Co in a research report on Wednesday, October 17th. Barclays upped their target price on shares of Eli Lilly And Co from $112.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, October 12th. Finally, Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $129.00 target price for the company in a research report on Tuesday, October 9th. Eight analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $111.53.
Shares of NYSE:LLY traded down $4.24 during midday trading on Tuesday, reaching $105.90. 6,802,014 shares of the company were exchanged, compared to its average volume of 4,224,195. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.09 and a current ratio of 1.40. Eli Lilly And Co has a one year low of $73.69 and a one year high of $116.61. The firm has a market cap of $114.65 billion, a price-to-earnings ratio of 24.74, a P/E/G ratio of 1.73 and a beta of 0.29.
Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.35 by $0.04. Eli Lilly And Co had a negative net margin of 0.60% and a positive return on equity of 39.84%. The firm had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same quarter in the prior year, the business earned $1.05 earnings per share. Eli Lilly And Co’s revenue for the quarter was up 7.1% on a year-over-year basis. As a group, research analysts predict that Eli Lilly And Co will post 5.47 earnings per share for the current year.
In other news, major shareholder Eli & Co Lilly sold 4,531 shares of the stock in a transaction on Monday, August 13th. The shares were sold at an average price of $14.33, for a total value of $64,929.23. Following the sale, the insider now owns 3,934,137 shares of the company’s stock, valued at $56,376,183.21. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Alfonso G. Zulueta sold 6,000 shares of the stock in a transaction on Tuesday, September 18th. The shares were sold at an average price of $106.31, for a total transaction of $637,860.00. Following the completion of the sale, the senior vice president now directly owns 55,224 shares in the company, valued at approximately $5,870,863.44. The disclosure for this sale can be found here. Insiders have sold 1,185,271 shares of company stock valued at $123,843,752 in the last quarter. 0.11% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Comgest Global Investors S.A.S. raised its stake in shares of Eli Lilly And Co by 17.2% in the third quarter. Comgest Global Investors S.A.S. now owns 1,547,900 shares of the company’s stock valued at $166,105,000 after acquiring an additional 227,200 shares during the period. Advisor Partners LLC raised its stake in shares of Eli Lilly And Co by 3.6% in the third quarter. Advisor Partners LLC now owns 26,003 shares of the company’s stock valued at $2,790,000 after acquiring an additional 893 shares during the period. Parametrica Management Ltd purchased a new stake in shares of Eli Lilly And Co in the third quarter valued at $265,000. Systematic Financial Management LP purchased a new stake in shares of Eli Lilly And Co in the third quarter valued at $2,123,000. Finally, Asset Planning Services Inc. LA ADV purchased a new stake in shares of Eli Lilly And Co in the third quarter valued at $249,000. 76.17% of the stock is currently owned by institutional investors and hedge funds.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Story: What is dollar cost averaging (DCA)?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.